Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Cardiac Amyloidosis With Diuretic-Refractory Pleural Effusions Treated With Bevacizumab

  • Bae, Suk-Hyang (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Hwang, Jin-Yeon (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Kim, Woo-Jae (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Yoon, Hyun-Hwa (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Kim, Jung-Min (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Nam, Young-Hee (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Baek, Hee-Gyung (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Cho, Yong-Rak (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Park, Sun-Yi (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Kim, Jeong-Hwan (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Kim, Sung-Hyun (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Park, Tae-Ho (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Lee, Gi-Nam (Department of Radiology, Dong-A University College of Medicine) ;
  • Rha, Seo-Hee (Department of Pathology, Dong-A University College of Medicine) ;
  • Kim, Young-Dae (Department of Internal Medicine, Dong-A University College of Medicine)
  • Received : 2010.02.25
  • Accepted : 2010.05.05
  • Published : 2010.12.30
⟨ Previous Next ⟩

Abstract

Cardiac amyloidosis describes a clinical disorder caused by infiltration of abnormal insoluble fibrils in the heart, characterized by progressive heart failure and a grave prognosis. Pleural effusion in cardiac amyloidosis may represent a sign of heart failure, but it can also result from pleural infiltration of amyloid, manifested by recurrent large fluid accumulations. Recently, the role of vascular endothelial growth factor (VEGF) has been implicated in the pathogenesis of refractory pleural effusion. We report a case of a 53 year-old female patient with cardiac amyloidosis who presented with recurrent accumulation of large pleural effusions. She was initially treated with high dose loop diuretics, but the pleural effusion persisted, with the daily amount of drainage averaging 1 L/day. Accumulation of pleural fluid did not subside after 3 cycles of melphalan/prednisolone therapy. After the introduction of bevacizumab, an anti-VEGF antibody, the amount of pleural effusion decreased significantly. Efficacy of anti-VEGF therapy for refractory pleural effusions needs to be defined through further studies.

Keywords

References

  1. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101-10. https://doi.org/10.1016/j.jacc.2007.08.028
  2. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-60. https://doi.org/10.1161/CIRCULATIONAHA.104.489187
  3. Kim YJ, Choi SO, Kim MK, et al. A case of familial cardiac amyloidosis. Korean Circ J 2004;34:520-6. https://doi.org/10.4070/kcj.2004.34.5.520
  4. Berk JL. Pleural effusions in systemic amyloidosis. Curr Opin Pulm Med 2005;11:324-8. https://doi.org/10.1097/01.mcp.0000162378.35928.37
  5. Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002;8:294-301. https://doi.org/10.1097/00063198-200207000-00009
  6. Sack U, Hoffmann M, Zhao XJ, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 2005;25:600-4. https://doi.org/10.1183/09031936.05.00037004
  7. Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med 2005;353:740-1.
  8. Hoyer RJ, Leung N, Witzig TE, Lacy MQ. Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol 2007;82:409-13. https://doi.org/10.1002/ajh.20858
  9. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis. J Am Coll Cardiol 2008;51:1022-30. https://doi.org/10.1016/j.jacc.2007.10.049
  10. Berk JL, Keane J, Seldin DC, et al. Persistent pleural effusions in primary systemic amyloidosis. Chest 2003;124:969-77. https://doi.org/10.1378/chest.124.3.969
  11. Smith RR, Hutchins GM, Moore GW, Humphrey RL. Type and distribution of pulmonary parenchymal and vascular amyloid: correlation with cardiac amyloid. Am J Med 1979;66:96-104. https://doi.org/10.1016/0002-9343(79)90488-1
  12. Bontemps F, Tillie-Leblond I, Coppin MC, et al. Pleural amyloidosis: thoracoscopic aspects. Eur Respir J 1995;8:1025-7.
  13. Kinasewitz GT. Transudative effusions. Eur Respir J 1997;10:714-8.
  14. Albertine KH, Wiener-Kronish JP, Staub NC. The structure of the parietal pleura and its relationship to pleural liquid dynamics in sheep. Anat Rec 1984;208:401-9. https://doi.org/10.1002/ar.1092080310
  15. Light RW, Hamm H. Malignant pleural effusion: would the real cause please stand up? Eur Respir J 1997;10:1701-2. https://doi.org/10.1183/09031936.97.10081701
  16. Mohammed KA, Nasreen N, Hardwick J, Logie CS, Patterson CE, Antony VB. Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2001;281:L119-25. https://doi.org/10.1152/ajplung.2001.281.1.L119
  17. Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM. Vesiculo-vacuolar barrier organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 1996;183:1981-6. https://doi.org/10.1084/jem.183.5.1981

Cited by

  1. The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion vol.15, pp.3, 2010, https://doi.org/10.1007/s11912-013-0315-7
  2. Transthyretin Ala36Pro mutation in a Chinese pedigree of familial transthyretin amyloidosis with elevated vitreous and serum vascular endothelial growth factor vol.110, pp.None, 2010, https://doi.org/10.1016/j.exer.2013.02.005
  3. Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases vol.18, pp.8, 2010, https://doi.org/10.1007/s12094-015-1464-y